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Abstract
Background: Evaluation of the efficacy and safety of a mandibular advancement device (MAD) (KlearwayTM) 
in the treatment of mild-to-moderate obstructive sleep apnea and chronic roncopathy. 
Material and Methods: A randomi�ed� �lacebo�controlled� double blinded� and crossover clinical trial was con�-
ducted. Placebo device (PD) defined as a s�lint in the centric occlusion that did not induce a mandibular ad-
vancement served as a control.  The mandible was advanced to the maximum tolerable distance or to a minimum 
of 65% of the maximum �rotrusion. After each sequence of treatment� �atients were assessed by questionnaires� 
conventional �olysomnogra�hy� and objective measurement of snoring at the �atient’s own home. 
Results: Forty two �atients �artici�ated in the study and 38 com�leted the study. Patients mean age was 46 ±9 
years and the 79% were males.  The mean mandibular advancement was 8.6 ±2.8 mm. Patients used the MAD and 
the PD for 6.4 +2.4 hours and 6.2 +2.0 hours, respectively. Secondary effects (mostly mild) occurred in the 85.7% 
and the 86.8% of the users of MAD and PD� res�ectively. The MAD induced a decrease in the a�nea�hy�o�nea 
index (AHI) from 15.3 +10.2 to 11.9 +15.5. The 50% reduction in the AHI was achieved in the 46.2% and the 18.4% 
of the �atients treated with MAD and PD� res�ectively. The use of the MAD induced a reduction in the AHI by 
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3.4 +15.9 while the PD induced an increase by 10.6 +26.1. The subjective evaluation of the ronco�athy indicated an 
im�rovement by the MAD and an increase in the �erce�tive quality of slee�. However� the objective evaluation of the 
ronco�athy did not show significant im�rovements. 
Conclusions: The use of MAD is efficient to reduce the AHI and im�rove subjectively the ronco�athy. MAD could 
be considered in the treatment of mild-to-moderate OSA and chronic roncopathy.
  
Key words: Obstructive sleep apnea (OSA), mandibular advance device, treatment, efficacy, clinical assay. 
Introduction 
The obstructive slee� a�nea (OSA) is a �revalent dis-
ease that affects in its severe form 2-8% of the general 
population. It is estimated that more than 20% of the 
�o�ulation has an a�nea�hy�o�nea index (AHI) value 
that is ≥ 5 (1,2). Clinical symptoms of OSA include 
somnolence, neuropsychiatric and cardio-respiratory 
disorders. These com�lications result from anatomical 
and functional alterations of the u��er airway where 
repetitive episodes of obstruction during sleep provoke 
oxihemoglobin desaturation and tem�oral arouses that 
lead to a none-reparative sleep (3).  
Many studies have established OSA as a risk factor for 
arterial hy�ertension and traffic accidents (2�4�6). The 
presence of OSA has also been related to cardiovascular 
and cerebrovascular complications (5,7,8).  Even more, 
higher mortality has been re�orted among �atients with 
OSA (9,10). In spite of all these consequences, OSA is 
still not adequately managed. Only 10% of the popula-
tion with OSA are diagnosed and treated (3�11,12). 
The administration of a continuous �ositive airway 
�ressure (CPAP) is an efficient� cost�effective treatment 
of OSA (3�13�14). There is a total agreement to indicate 
this treatment in �atients with AHI > 30 who suffer from 
com�lications related to the OSA (3). However� the in-
dication of the CPAP in �atients with mild�to�moderate 
OSA (AHI = 5-29) is not that clear (3,14,15). 
The mandibular advancement device (MAD) is consid-
ered as an alternative to the CPAP (3). This device� also 
designed to alleviate and treat roncopathy, provokes the 
protrusion of the mandible in order to elevate and ad-
vance both the hyoid bone and the tongue. By this, the 
volume of the u��er airway is increased making less 
likely the �assage  narrowing or colla�se (16). Several 
studies have recommended the treatment of mild-to-
moderate OSA by MAD and have also indicated its use 
in �atients with severe OSA intolerable to the CPAP 
(3�17�18). However� there is still a need for randomi�ed 
controlled clinical trials to establish with more �reci-
sion the indications and the efficacy of the MAD in the 
treatment of OSA. 
In this study, a randomized controlled crossover clini-
cal trial has been �erformed to evaluate the efficacy and 
safety of mandibular advancement device in the treat-
ment of �atients with mild�to�moderate OSA. A �lacebo 
device (PD) has been used as a control. 
Material and Methods 
* Patients 
Randomized, placebo-controlled, double blinded, and 
crossover clinical trial was conducted at the Interdis-
ciplinary Unit of Sleep Disorders of Alava University 
Hos�ital. The study �rotocol and informed consent� in 
full accordance with the ethical �rinci�les of the Decla-
ration of Helsinki of 1975� as revisited in 2000� were a�-
proved by the ethical committee of University Hospital 
of Álava (Vitoria-Gasteiz, Spain). 
Patients were consecutively selected from adult subjects 
referred due to a clinical suspicion of OSA. Patients 
from both sexes were eligible to �artici�ate in this study 
and were selected according to the following inclusion 
criteria:
- Age higher than 18 years, 
- Presence of chronic snoring. A patient is considered 
as chronic snorer if his/her bedmate/roommate reported 
to snore more than 5 days �er week and this is corrobo-
rated by a respiratory polygraphy performed in the pa-
tient’s own home. The result of the res�iratory �olyg-
raphy should indicate the presence of snoring during at 
least 30% of the nocturnal period.
- Confirmed diagnosis of mild�to�moderate OSA (5 ≤ 
AHI < 30) by polysomnography (PSG). 
- Have a roommate or bedmate to submit information. 
Patients were excluded according to the following ex-
clusion criteria:
- High-risk professions and/or controlling dangerous 
machines.
- Moderate or severe somnolence during day time.
- Coronary cardiopathy, acute vascular disease (less than 
three months), chronic and severe obstructive pulmonary 
disease� and chronic treatment with theo�hyllines. 
- Tem�oro�mandibular joint �roblems or �eriodontitis.
- Mandibular protrusion capacity less than 6 mm and/or 
less than 10 teeth in each jaw.
� Severe cognitive disorders and/or �atients whose an�-
swers to the questionnaires will be altered by chronic 
and severe diseases.
- Pregnancy (since the third month of pregnancy to 3 
months after birth delivery).
A total of 118 �atients were screened� of whom 76 were 
not eligible: 62 did not meet the inclusion criteria or had 
one or more of the exclusion criteria� and 7 declined to 
participate (Fig. 1).
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Forty�two �atients were randomly assigned to receive 
two �ossible sequences of treatment (MAD or �lace�p -
bo device (PD) according to a computer-generated 
randomi�ation schedule. To achieve a double�blinded 
study, professionals not related to the interventions and 
o�aque�sealed envelo�es were ado�ted. The dentists 
and ENT surgeons� res�onsible of device fabrication� 
ada�tation� and following u� of the �atients� had no 
contact during the clinical trial with the �rofessionals 
who �erformed the slee� study. All the controls and the 
results of the tests were code identified and were only 
known by a one �rofessional who did not �artici�ate in 
the clinical trial. 
Initially� each �atient were subjected to a �eriod of 2 
weeks without any treatment� followed by 4 weeks of 
adaptation and standardization of the device (MAD 
or PD)� and 12 weeks of treatment (Fig. 1). Once this 
�eriod was finished� �atients were switched to use the 
other device following the same �rotocol as described 
above (Fig. 1).
Mandibular advancement device (MAD): The commer-
cial device KlearwayTM (University of British Colum-
bia� Vancouver� Canada) was used. The fabrication of 
the device was made on model casts of both jaws and 
was ada�ted to the �atient’s mouth by a dentist with the 
objective to achieve a sufficient and tolerable mandibu-
lar advancement� being at least 65% of the maximum 
�rotrusion ca�acity of the mandible. This �hase may 
need more than one visit to the dentist and had a period 
of 4 weeks at maximum. 
Placebo device (PD): The �lacebo device was the same 
KlearwayTM device but in centric occlusion and did not 
�rovoke mandibular advancement. The dentist assured 
the absence of mandibular advancement and alteration 
to the TMJ �osition. The reference �oint was jaw �osi-
tion at the TMJ level in rest as measured by ce�halom-
etry. The PD ada�tation may need more than one visit 
to the dentist and had a �eriod of 4 weeks at maximum. 
* Primary outcome
The �rimary outcome was the a�nea hy�o�nea index 
(AHI) that was measured by a conventional �olysom-
nogra�hy (PSG). The PSG study was reali�ed at the 
Interdisciplinary Unit of Sleep Disorders of Alava Uni-
versity Hos�ital. The PSG study was �erformed before 
the study and after the 12 weeks of the treatment with 
each device (MAD and PD). 
All slee� studies were �erformed with PSG (Alice 
3 Healthdyne system) according to the standard pa-
rameters of electroencephalogram (C3-A2, C4-A1), 
electrooculo gram, submentonian and tibial electromy-
ogram� electrocardiogram (modified V2)� res�iratory 
effort (thorax and abdominal resistance)� air flow (na-
sal and oral thermistor)� Oxygen saturation (cutaneous 
�ulsioximetry with a finger �robe (Palco laboratories 
P�340) and snore micro�hone. The PSG study was man�-
ually interpreted in periods of 30 seconds according to 
the criteria of the American Academy of Sleep Studies 
(19) and  following the guidelines of the S�anish Soci-
ety of Pneumology and Thoracic Surgery (SEPAR) (3). 
The minimum time of recording was 6 hours and the 
Fig. 1. Study flow chart.
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minimum time of slee� was 180 minutes. The following 
definition of the res�iratory variables were used: 
� A�nea: The com�lete sto� (> 90%) of the naso�oral 
airflow during a minimum of 10 seconds. The a�nea 
was then classified as obstructive if it was accom�anied 
by thoracic and abdominal effort, central if this effort 
was absent and mixed if both situations occurred in one 
single apnea.
� Hy�o�nea: A dro� in the res�iratory signal between 
30% and 90%� accom�anied by a dro� in oxygen satura-
tion ≥ 3% and/or arousal. 
* Secondary outcomes:
Sleep characteristics: the total sleep time, the time of the 
�artial �hases of slee� (N1� N2 and N3) and the REM 
�hase were calculated from the PSG study. The slee� 
fragmentation was measured by the arousal index.
Oxygen saturation: Cutaneous �ulsioximetry with 
a finger �robe (Palco laboratories P�340) was used to 
measure this variable during the performance of the 
PSG study. This variable was described by the mean 
oxygen saturation� minimum oxygen saturation and the 
�ercentage of time s�ent at SaO2 below 90% (CT90).
Snoring: On one hand both patient and bedmate/room-
mate were asked to evaluate the �atient’s ronco�athy by 
answering a questionnaire after finishing the treatment 
with each device. The question was How is your snor-
ing? The �ossible answers were 1. Have increased a lot� 
2. Have increased slightly, 3. Have not changed, 4. Have 
decreased slightly, and 5. Have decreased a lot. On the 
other hand, validated respiratory polygraphy system 
(Mesam IV) was used for the objective evaluation of the 
snoring habit (2). This system had the ca�acity to save 
information of 18 hours of recording. The snoring was 
measured by a protected microphone placed at the yu-
gulum. The micro�hone filtered the sounds between 50 
y 800 cycles/second as snoring sounds occurred in this 
range. If the volume of the sound is higher than 50% of 
the total volume� the sound was then identified as snore. 
If the sound exceeded a threshold of > 1.1 mV and 1000 
cycles/second� it was then considered as strong snore. 
The data was �rocessed by a �ersonal com�uter and 
could be printed. 
The system �ermitted an automatic or manual reading 
of the recordings in �eriods of 10 minutes. The study 
with Mesam IV was �erformed before treatment and af-
ter the 12 weeks of treatment with each device (MAD 
and PD). The snoring was described by measuring the 
intensity, number of snores per hour of recording, per-
centage of time of recording with evidence of snoring 
and its relationshi� with body �ostures during slee�. 
Somnolence: the E�worth scale was used to measure 
the somnolence. The questionnaire also included other 
questions: Comparing to the situation before treatment 
how are you during the day? Com�aring to the situation 
before treatment how is your humor? The roommate 
was s�ecifically asked about his slee� in com�arison to 
the he/she had before treating the �atient. The answer 
for all these questions was selected from the following 
o�tions: 1. Much worse; 2. Slightly worse; 3. No chang-
es; 4. Slightly better; and 5. Much better.
Treatment com�liance: it was evaluated by calculating 
the time of device use. This time was obtained from the 
�atient s´ declaration and in a consensus with the room-
mate. If there was no consensus� the �atent’s declara-
tion was considered as valid. Since the beginning of the 
study, patients had been phone called once per month 
to evaluate the treatment progress and patients adher-
ence to the treatment. The use of the device was deter-
mined by the number of nights �er week and the average 
number of hours of use per night since the last control. 
The average time of use of the device �er hour was es-
timated by the multiplication of both variables and then 
the result was divided by 7. However� if the �atient had 
used the device for different time between weeks� an 
average was calculated �er each week and then the re-
sults were used to calculate the mean. It was considered 
a good adherence to the treatment if the mean time of 
use was ≥ 4 hours �er night as described by the study of 
Ferguson et al. (20). 
Complications: the nature, onset, duration, severity, and 
the outcomes of all adverse events� as well as any asso-
ciation of an adverse event related to the device (MAD 
and PD) were assessed and documented. In order to 
evaluate the safety �rofile of the treatments� all com-
�lications and/or adverse events were recorded with an 
accountability scale. 
* Sample size calculation
The sam�le si�e was determined by taking in considera-
tion the crossover design of the study. The objective was 
to be able to detect the minimum effect of the device on 
the variables of �ercentage of �atients with AHI > 5� 
the distribution of AHI, the distribution of number of 
snores per hour of sleep and the percentage of patients 
with snoring.  The calculation was �erformed consider-
ing α value of 0.05� statistical �ower (1�β) of 90% and 
bilateral hypothesis test. 
A sam�le si�e of 40 subjects would result in a statisti-
cal �ower higher than 90%. In the case of AHI� a sam-
ple size of 40 patients permitted detecting a minimum 
difference of 9.5 in agreement with the data re�orted 
by Clark et al. (21) and Ferguson et al. (20) giving a 
standard deviation of 18 and the application of paired t-
student test. In the case of number of snores per hour of 
sleep objectively measured in bed, a sample size of 40 
patients permit detecting a minimum difference of 12.4 
giving a standard deviation of 24.1.
* Statistical analysis 
The t�student test was used to com�are the character-
istics between grou�s. Paired t�student and analysis 
of variance were used for the com�arison of continu-
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ous variables of �aired sam�les. McNemar’s test was 
applied to see if the devise use had am effect over the 
AHI. Linear and multi�le regression analysis were used 
for the crossover design and to examine the relationshi� 
between variables. The evaluation of the results was 
performed considering the potential effect of the period 
and the results were ex�ressed for intention to treat and 
for every protocol. 
Results
Figure 1 describes the study flow chart. During a re-
cruitment �eriod of 6 months� 112 �atients were evalu-
ated. Sixty�three �atients were excluded as they did not 
complete the inclusion criteria or had one or more of 
the exclusion criteria. Seven �atients refused to �artici-
�ate in the study. Forty�two �atients �artici�ated in the 
study and 38 patients (90.5%) completed all phases of 
the study. Four �atients (9.5%) (2 men and 2 women) 
abandoned the study due to intolerance and/or second-
ary effects of the device. 
Table 1 shows the �atients characteristics at the dif�-
ferent �hases of the study (ada�tation� treatment with 
MAD and treatment with PD). Patients had a mean age 
of 46 ±9 years and 33 (79%) were males. There was no 
statistically significant difference in relation to the an-
thropometric characteristics and the clinical variables 
between the different �hases of the study. However� a 
discrete increase in the mean body mass index was de-
tected between the ada�tation and �lacebo �hases. This 
increase was from 27.7 ±3.2 to 29.3 ±9.2 (p < 0.05).  The 
MAD achieved a mandibular �rotrusion of 8.6 ±2.8 
mm. It was notorious the decrease in alcohol consum�-
tion between the ada�tation and treatment �hases for 
both study arms (p < 0.05). 
Table 2 shows the results of PSG at the different �hases 
of the study. Neither MAD nor PD modified signifi-
cantly the slee� duration� intensity or efficacy. Moreo-
ver� the com�arison between the ada�tation �hase and 
the treatment phase in both study arms (MAD and PD) 
showed the absence of statistically significant differenc-
es in the total sleep time, the time of the partial phases 
of slee� (N1� N2 and N3) and the REM �hase. The slee� 
fragmentation� measured by the arousal index� was not 
reduced by the treatment with MAD. However� it was 
significantly increased by the treatment with PD. 
The analysis of the res�iratory events showed that 
MAD reduced the AHI from 15.3 +10.2 to 11.9 +15.5. 
This reduction was not statistically significant (p = 
0.196). Whereas, the PD incremented the AHI to 25.6 + 
26.0 and this increase was statistically significant (p = 
0.016). Worth to mention� the use of MAD significantly 
reduced most of the res�iratory events when com�ared 
to the PD as shown in table 2. For exam�le� the 50% 
reduction in the basal AHI was achieved in 46.2% of the 
cases treated with MAD in com�arison to the 18.4% for 
the PD. Values of AHI < 5 was achieved by MAD in the 
31.6% of the cases in comparison to the 15.8% for the 
PD. There were no statistically significant differences 
Characteristics
Basal phase       
(n=42) 
MADa        
(n=39) 
PDb   (n = 38) 
Age  (years) 46.5 + 9.3 46.2 + 9.1 46.8 + 9.2 
Men  (n and %) 33 (78.6) 32 (82.1) 31 (81.6) 
Body Mass Index† 27.7 + 3.2 28.0 + 3.2 29.3 + 9.2§
E�worth Slee�iness Scale (0�24) 12.2 + 4.3 10,3 + 4,2 9,8 + 4,4 
Systolic blood pressure (mmHg) 123.8 + 9.9 123.6 + 18.5 125.9 + 15.6 
Diastolic blood pressure (mmHg) 82.8 + 6.5 84.1 + 9.8 85.5 + 10.8 
Active smokers (n and %) 17 (40.5) 17 (43.6) 17 (44.7) 
Alcohol consumption (ethanol g/ day) 20.3 + 22.8 14.7 + 21.6‡ 11.1 + 15.1§
Caffeine consumption (number of cups a day) 1.88 + 1.78 1.92 + 1.80 1.89 + 1.81 
Table 1. Characteristics of the study population.
aMandibular advancement device.                                                                          
bPlacebo device.                                                                                                         
†Body mass index is defined as the weight in Kg divided by the square of height in mm.                                                                                            
‡p < 0.05 for comparison of basal phase Vs MAD phase.                                                                      
§p < 0.05 for comparison of basal phase Vs MAD phase.
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when the variables of mean oxygen saturation� mini-
mum oxygen saturation and CT90 were com�ared be-
tween the ada�tation �eriod and device�using �hases. 
The �eriod effect was also evaluated by com�aring 
the mean difference in the AHI of the patients initially 
treated with PD and the �atients initially treated with 
MAD. The statistical analysis showed no significant 
differences. Additionally, the carryover effect and the 
interaction between the treatment and the �eriod were 
also evaluated using the mean AHI after the use of 
MAD and PD. The results also showed the absence of a 
significant differences (data not shown).
Table 3 describes the evolution of the roncopathy for the 
arms of the study. The evaluation was �erformed sub-
jectively (questionnaire) and objectively (Mesam IV). 
The use of the MAD resulted in a significant reduction 
in the perception of snoring and increases the perceived 
quality of slee� when evaluated by both the �atient and 
the bedmate/roommate. However� the objective evalua-
tion showed no significant changes in the snoring char-
acteristics. 
The com�liance with the use of device was 6.4 + 2.4 
hours for the MAD and 6.2 + 2.0 for the PD (p > 0.05). 
The 87.1% and the 76.3% of the �atients used the MAD 
and PD res�ectively for more than 5 hours/night (Table 
3).  
The secondary effects from the use of both s�lints are 
shown in table 4. Both s�lints induced the occurrence of 
relevant secondary effects (86.8% for the PD and 85.7% 
for the MAD). The 52.6% and 57.1% of these effects 
were mild for the PD and MAD� res�ectively. Severe 
secondary effects (irreversible alteration of the occlu-
†CT90 is the �ercentage of the total slee� time s�ent with a SaO2 below 90%.                                        
aMandibular advancement device.                                                                         
bPlacebo device.                                                                                                              
‡p < 0.05 for comparison of basal phase Vs MAD phase.                                                                      
§p < 0.05 for comparison of basal phase Vs MAD phase.                                                                   
¶p < 0.01 for comparison of MAD phaseVs PD phase.
Table 2. Outcomes of the analysis of the conventional polysomnography (PSG).*
Characteristics
Basal phase     
(n=42) 
MADa         
(n=39) 
PDb            
(n=38) 
Total slee� time (minutes) 372.6 ± 68.5 368.3 ± 49.1 363.9 ± 68.3 
Efficacy of slee� (%) 87.1 ± 7.8 88.8 ± 7.8 88.9 ± 7.8 
N1 stage (minutes) 18.1 ± 10.3 15.2 ± 14.8 15.1 ± 9.5 
N2 stage (minutes) 235.7 ± 53.7 223.6 ± 56.5 237.9 ± 59.4 
N3 stage (minutes) 33.0 ± 16.3 32.7 ± 20.8 27.9 ± 22.9 
REM  slee� (minutes) 81.6 ± 26.1 83.0 ± 35.3 80.7 ± 27.9 
Arousal index  17.9 ± 5.9 18.3 ± 7.8 26.8 ± 13.7§
A�nea�hy�o�nea index (AHI) 15.3 + 10.2 11.9 + 15.5¶ 25.9 + 26.0§
Total number of a�nea�hy�o�nea events 96.3 ± 66.4 71.4 ± 91.8¶ 165.6 ± 170.4§
Number of obstructive a�neas �er hour 24.8 ± 31.1 18.7 ± 38.7¶ 46.8 ± 58.1§
Number of central a�nea �er hour 11.2 ± 17.7 4.4 ± 8.0‡ 19.0 ± 50.2 
Number of mixed a�neas �er hour 3.8 ± 7.2 4.1 ± 12.1¶ 12.0 ± 26.2§
Number of hyo�o�nea events 57.3 ± 42.9 45.1 ± 50.4¶ 89.1 ± 98.1 
Average duration of a�nea and hy�o�onea events  16.5 ± 2.6 16.9 ± 3.5 20.9 ± 12.7§
Reduction in the AHI > 50% (%) � 46.2¶ 18.4 
Increase in the AHI > 50% (%) � 10.3¶ 31.6 
AHI < 5 / hora (%) - 31.6¶ 15.8 
AHI < 10 / hora (%) - 57.9¶ 44.7 
Mean SaO2 (mmHg) 92.4 + 12.3 94.2 + 1.6 93.5 + 1.7 
Minimum SaO2 (mmHg) 87.1 + 4.4 85.7 + 5.5 83.3 + 7.1 
CT90  3.2± 13.8 2.3 + 5.40 3.8 ± 6.7 
Snoring time (%) 60.9 ± 24.2 55.0 ± 30.8¶ 71.6 ± 27.1§
Med Oral Patol Oral Cir Bucal. 2015 Sep 1;20 (5):e605-15.                                                                                                                                                                       MAD in the treatment of OSA
e611
sion) were only observed in 5 �atients due to the use of 
MAD.  Table 4 also showed that the secondary effects 
tended to be higher when the MAD was used.
Figure 2 shows the com�arison of the mean AHI be-
tween the basal �hase with the PD and MAD �hases. 
This com�arison revealed a significant increase in the 
AHI by the PD (p = 0.017) and a reduction in the AHI, 
although not statistically significant� was observed in the 
Characteristics
MADa         
(n=39) 
PDb           
(n=38) 
Patients declared to sleep better  23 (60.5%)§ 11 (28.9%) 
Patients declared to snore lesser  36 (94.7%)¶ 18 (47.4%) 
Patients declared to feel better during the day time 18 (47.4%) 11 (28.9%) 
Patients declared to have better mood 8 (21.0%) 7 (18.4%) 
Roommates declared that patient snore lesser 34 (87.2%)¶ 19 (50.0%) 
Roommates declared that patient sleep better 29 (74.3%)¶ 12 (31.6%) 
Roommates declared that patient feels better during the day time 21 (53.9%)¶ 5 (13.2%) 
Roommates declared that the patient has a better mood 11 (28.2%) 6 (15.8%) 
Reduction in the number of snores/hour > 50% 15.8% 8.1% 
Increase in the number of snores/hour > 50% 26.3% 37.8% 
> 50% decrease in the total number of snores �er hour 23.7% 8.1% 
> 50% increase in the total number of snores �er hour 21.1% 32.4% 
Reduction in the percentage of registration time with snoring > 50% 24.2% 11.4% 
Increase in the �ercentage of registration time with snoring > 50% 30.3% 45.7% 
Table 3. Results of snoring evaluation.
aMandibular advancement device.         
bPlacebo device.                                                        
‡p < 0.05. 
§p < 0.01.                                                                                                                         
¶p < 0.001.
MAD �hase. When both s�lints were com�ared� the use 
of MAD reduced significantly the AHI (p = 0.000). Fig-
ure 3 shows the results of the mean change in the AHI. 
An increment in the AHI by 10.6 + 26.1 was caused by 
the PD while a reduction by 3.4 + 15.9 was caused by the 
MAD. The differences between the PD and the MAD 
were statistically significant ( p = 0.000).
Discusion
The �rinci�al finding of this study is that mandibular 
advancement device, in comparison to a PD, has pro-
duced a significant enhancement in all the �arameters 
that measure the respiratory events. As a secondary out-
come� the MAD has reduced significantly the chronic 
ronco�athy when evaluated by the bedmate/roommate. 
However� this reduction was not significant when the 
snoring was objectively measured. 
In the last years several review studies have been �ub-
lished to evaluate the use of the MAD in the treatment 
of OSA (17-22). All these studies have concluded that 
this device has a positive effect in reducing the AHI but 
is inferior to the CPAP treatment (22). For that, there 
is no doubt that MAD is a reasonable alternative to the 
CPAP in �atients with mild�to�moderate grade of OSA 
and in �atients with severe OSA intolerant to the CPAP 
(22). 
Although there are numerous clinical trials on the effi-
cacy of MAD in �atients with OSA� some issues remain 
unresolved. It is difficult to �redict the ty�e of �atients 
who could maximally benefit from the use of MAD by 
having the highest tolerance to the splint and the least 
number of secondary effects (22).
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Herein� when com�ared to PD� the MAD has signifi-
cantly im�roved all res�iratory �arameters. The device 
reduced the absolute number of apnea and hypopnea as 
well as the AHI. The decrease in the AHI by more than 
50% was achieved in almost half of the �atients treated 
with MAD. AHI < 10 and AHI < 5 were achieved for 
the 57.9% and the 31.6% of �atients treated with MAD 
and PD, respectively. Similar results have been reported 
by other controlled clinical trials (20�21) confirming the 
efficiency of MAD in the treatment of mild�to�severe 
OSA. 
The selection of the ty�e of the mandibular advance-
ment device has been evaluated by several studies. Si-
milar results have been reported by clinical trials that 
use two��iece design of the s�lint and trials that use 
mono-block designs (23). Recently, adjustable MAD 
(805 �atients) and fixed (203 �atients) have been com-
�ared in a retros�ective study. The im�rovement in the 
OSA was better for the adjustable device than the fixed 
device (56.8% Vs 47.0%) (24). 
Herein� an adjustable MAD was used to achieve the 
maximum and tolerable mandibular advancement (a 
minimum of the 65% of the maximum mandibular �ro-
trusion). This was ada�ted to reduce the number and/
or intensity of the adverse events, minimize the injury 
to the temporomandibular joint and obtain better out-
comes. A dose-response effect has been reported for the 
MAD, the more advancement of the mandible better is 
the response (25). In this study, the mean mandibular 
advancement was 8.8 + 2.8 mm. 
Although it has been re�orted that when 50% of the 
maximum �rotrusion is achieved� there is a tendency 
for the secondary event to increase. In our study, 65% of 
the maximum �rotrusion has been achieved and the �er-
centage of secondary effects has been similar to other 
studies (20,22).
One of the consequences of OSA is the loss of sleep ar-
chitecture; lesser �ro�ortion of �rofound slee� (N3) and 
REM� and increase in the arousal index as ex�ression 
of slee� fragmentation (3). The findings of this study 
Secondary effects of splint use 
MADa       
(n=39) 
PDb           
(n=38) 
Patients with secondary effects 85.7% 86.8% 
Mild secondary effects 24 (57.1%) 20 (52.6%) 
Moderate secondary effects 7 (16.7%)‡ 13 (34.2%) 
Severe secondary effects 5 (11.9%)§ 0 (0%) 
Hypersalivation 15 (35.7%)§ 22 (57.9%) 
Dental or gingival pain 7 (16.7%)‡ 4 (10.5%) 
Pain in the tongue  3 (7.1%)‡ 4 (10.5%) 
Tem�oral Bite change 5 (11.9%)§ 2 (5.3%) 
Pain in the temperomandibular joint 3 (7.1%)§ 1 (2.6%) 
Mouth dryness 2 (4.8%)‡ 1 (2.6%) 
Unespecific splint intolerance 3 (7.7%)§ 0 (0%) 
Damage to dental restorations 2 (5.1%)‡ 1 (2.6%) 
Splint fracture 3 (7.7%) 2 (5.3%) 
S�lint wearing (nº horas �or noche) 6.4 + 2.0 6.2 + 2.0 
S�lint wearing > 5 hours �er night (n; %) 34 (87.1) 29 (76.3)  
Table 4. Secondary effects and com�liance with s�lint usage.  
aMandibular advancement device.                                                                          
bPlacebo device. 
‡p < 0.05. 
§p < 0.01.
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Fig. 2. Effects of the device on the a�nea�hy�o�nea index (AHI). Basal time (BT)� �lacebo device (PD) and 
Mandibular Advancement device (MAD).
Fig. 3. Effects of the device on the net change in the a�nea�hy�o�nea index (AHI). The results were cal-
culated as the difference between the AHI at basal time and the AHI after the use of the device. Placebo 
device (PD) and Mandibular Advancement device (MAD). 
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indicated the absence of differences in the sleep charac-
teristics� which could be related to the mild�to�moderate 
grade of OSA. Singh et al. (26) have found significant 
reduction in the arousals in OSA �atients treated with 
MAD but the patients in that study had more severe 
sleep fragmentation (50.8 + 31.0) than our study. Re-
garding the oxygen saturation� the mild�to�moderate 
severity of OSA could also contribute to the absence of 
significant effect of the MAD (27). 
Some studies have reported that the MAD produces a 
reduction in the values of arterial tension and improve-
ments in the excessive daytime slee�iness (22). In our 
study� the MAD did not significantly alter these �aram-
eters nor the PD. Possibly, the severity of OSA (mild to 
moderate) could contribute to this finding. 
With respect to the roncopathy, different studies have 
re�orted relevant im�rovements when MAD is used 
(28). The subjective evaluation of the snores has indi-
cated a relevant im�rovement (about 90%). However� 
the objective evaluation has only shown mild and not 
significant im�rovements. This discre�ancy could be at-
tributed to the differences in the tolerance to the snores. 
During the objective evaluation, the system evaluates 
the �resence/absence of snore but not its intensity. This 
means that a snore may persist but the reduction in its 
intensity would make it tolerable to the �atient and the 
roommate/bedmate. However� Adriana et al. (27) have 
found improvements in the objective evaluation of the 
snores. This could be attributed to the fact that the basal 
situation of the patients in the study by Adriana et al. 
(27) was higher than the �atients in our study and thus 
had more room for im�rovement. The snores/hour index 
was 40.4 and 24.5� res�ectively. 
The secondary effects due to the use of the MAD were 
frequent. These effects were �resent in the 86% and 
87% of the �atients treated with MAD and PD� res�ec-
tively. Although there were no significant differences 
between the grou�s� these secondary effects tend to be 
more severe in the MAD group. 
Most of the secondary effects were mild to moderate. 
They were a subjective com�laints of hy�ersalivation� 
mouth dryness, gingival pain, dental pain, lingual pain, 
or TMJ �ain. This is in agreement of the findings of �re-
vious studies (22). However� severe secondary effects� 
referred to as an irreversible alteration of the occlusion, 
occurred in 5 �atients due to the use of MAD. There 
was no association between the subjective com�laints 
of the patients and the severe secondary effects. Data 
from the literature could suggest that irreversible occlu-
sal alterations are related to the time of use of the MAD 
(21). This suggestion could not be evaluated in the study 
as the follow�u� time was limited to 12 weeks in each 
arm of the trial. 
One of the aspects related to the use of the MAD is the 
relative inca�acity to �redict which �atients would ben-
efit from the use of MAD and which not. It seems there 
is an individual variation in the response to a treatment 
with MAD (22). Some variables have been observed to 
be associated with the best res�onse to a treatment with 
MAD. Of these variables are lower severity of the AHI� 
�ostural OSA� lower age� feminine gender� and lower 
obesity (22). Due to the relatively small sample size, 
inherent to a clinical trial� it was im�ossible to iden-
tify variables with a ca�acity to �redict the res�onse to 
the MAD. It is �ossible that the new techniques of im-
age evaluation of the u��er airway �lay a role in iden-
tifying �atients that res�ond well to a treatment with 
MAD. This should be considered as �riority in the clini-
cal research in this field (29). Even is more intriguing 
the fact that in some �atients if treated with MAD the 
AHI is worsened. The findings of this study indicated 
that 10.3% of the �atients with MAD had their AHI in-
creased by 50%, in comparison to the 31.6% in the case 
of the PD. This has been also observed in other stud-
ies (30). The etiology of such a res�onse to the MAD 
is not totally understood and has been related to ana-
tomical changes particularly in the position of the hyoid 
bone. This would make em�hasis in the im�ortance of 
performing a sleep study to monitor the outcomes of a 
treatment with MAD. 
This randomi�ed clinical trial has recruited 38 �atients� 
a sample size that has been adequate to meet the study 
objectives. However� this sam�le si�e did not allow for 
patients subgrouping to identify factors that could be 
associated with a good res�onse to the treatment with 
MAD.  The criterion of maximum mandibular advance-
ment� that was limited to a minimum of 65% of the 
maximum mandibular �rotrusion� was arbitrarily estab-
lished. It is possible that lesser mandibular advancement 
could obtain similar results but with fewer secondary 
effects. Future research would test this hy�othesis and 
establish a criteria to maximi�e the benefits and mini-
mize the secondary effects. An important limitation to 
this study is that the used PD has not been a truly pla-
cebo (the results of the slee� study were affected by the 
PD). This limitation should be considered when analy�-
ing the results of this clinical trial. 
Within the limitation of this study, the use of MAD is 
efficient to reduce the AHI y im�rove subjectively the 
ronco�athy. Thus� MAD could be considered in the 
treatment of mild-to-moderate OSA and chronic ronco-
pathy. Further studies should evaluate the hypothesis of 
obtaining similar outcomes at minimal secondary ef-
fects when shorter mandibular advancement is achieved. 
Studies with larger sam�le si�e are still needed to estab-
lish the �atient �rofile that could be associated with a 
good res�onse to a treatment with MAD. 
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